New Two-Drug attack tested for tough liver cancers
NCT ID NCT06354387
Summary
This small, early-stage study tested whether combining two existing cancer drugs (alectinib and nivolumab) could help control advanced liver cancer that had stopped responding to standard treatments. It involved just 5 patients with recurrent or treatment-resistant liver cancer. The main goal was to see if the treatment was safe and if a specific blood marker (RNase1) could predict which patients might benefit.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CMUH
Taichung, Taiwan
Conditions
Explore the condition pages connected to this study.